For investors to ride along with a management team that has been putting their
money where there mouth is by investing their own money in the stock.
Exciting news pending:
Potential FDA approval of ThermoDox for the treatment of primary liver cancer, depending on clinical results.
Top-line release of colorectal liver metastases data from 92 patients in Phase II trials.
Celsion Corporation (CLSN), little financial and a pipeline portfolio with a bright future. According to analyst opinions and pipeline studies, the expected target price will reach $18
"Thermodox could work in most of cancer types. The estimations would be up to billions of dollars annually.
On June 19, 2012, Celsion Chief Executive Michael Tardugno said:
There is a chance if we execute perfectly here that we could be seeing an approval by the end of 2013. Certainly this is a $1 billion drug."
Celsion is a company with some very promising studies and a large potential market. It is really difficult to find a biotechnology company with such a reduced debt, but also with such advanced studies against cancer. The target price of Celsion continues to be $9 for the short term. In my opinion, Celsion could be above two digits in the long term.
Celsion has licensed exclusive world-wide rights to the proprietary lipid technology and has IP protection until 2018. Additionally, the orphan drug designation provides Celsion with 7 years of exclusivity in the U.S.and 10 years of exclusivity in Europe.